Menu
Search
|

Menu

Close
X

Galmed Pharmaceuticals Ltd GLMD.OQ (NASDAQ Stock Exchange Capital Market)

15.00 USD
-0.02 (-0.13%)
As of Jul 20
chart
Previous Close 15.02
Open 15.49
Volume 253,590
3m Avg Volume 125,106
Today’s High 15.95
Today’s Low 14.91
52 Week High 27.06
52 Week Low 3.61
Shares Outstanding (mil) 12.64
Market Capitalization (mil) 117.83
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.88 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
0
FY15
0
EPS (USD)
FY17
-0.985
FY16
-1.487
FY15
-0.957
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
117.24
5.73
Price to Book (MRQ)
vs sector
18.24
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-137.95
14.61
Return on Equity (TTM)
vs sector
-140.43
16.34

EXECUTIVE LEADERSHIP

Chaim Hurvitz
Chairman of the Board, Since 2011
Salary: --
Bonus: --
Allen Baharaff
Chief Executive Officer, Director, Since
Salary: --
Bonus: --
Antony Appleyard
Vice President – Drug Development, Since
Salary: --
Bonus: --
Maureen Graham
Vice President - Regulatory, Since 2012
Salary: --
Bonus: --
George Tonelli
Vice President - Clinical Operations, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

16 Ze'ev Tyomkin St. (4Th Fl.)
TEL AVIV-YAFO     6578317

Phone: +9723.6938448

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.

SPONSORED STORIES